Forian Inc. (Nasdaq: FORA), a leader in data science and analytics for the life sciences and healthcare industries, announced its financial results for the third quarter ended September 30, 2024. The company reported a revenue of $4.7 million, marking a 12% decrease from the $5.3 million recorded in the same period the previous year. This quarter also saw a net loss from continuing operations of $204,907, or $0.01 per share, a stark contrast to the net income of $5.5 million, or $0.16 per share, reported in Q3 2023.
Despite the downturn, Forian's leadership remains optimistic about the company's strategic direction. Max Wygod, Chairman and CEO of Forian, emphasized the team's dedication to long-term value creation and the strategic acquisition of Kyber Data Science. This move is expected to enhance Forian's analytics offerings and market reach, positioning the company favorably for future opportunities.
Adjusted EBITDA for the quarter stood at $185,916, down from $1.1 million in the prior year period. However, Forian concluded the quarter with a robust cash position of $49.4 million in cash, cash equivalents, and marketable securities, providing a solid foundation for ongoing operations and strategic initiatives.
A significant development during the quarter was the acquisition of Kyber Data Science on October 31, 2024. This acquisition is poised to broaden Forian's portfolio with advanced machine learning-powered analytics solutions, catering to a wider array of market needs. Additionally, the company made strides in strengthening its financial position by redeeming over $15 million of its 3.5% Convertible Notes in October and November 2024, following $950,000 in redemptions during the third quarter.
Operating expenses saw a slight reduction to $5.5 million in Q3 2024 from $6.2 million in Q3 2023, attributed to decreased sales and marketing expenditures and lower general and administrative costs. Forian's total assets as of September 30, 2024, were reported at $57.5 million, with total liabilities at $30.6 million.
Looking ahead, Forian is focused on leveraging its enhanced capabilities post-Kyber acquisition to drive growth and capitalize on the growing demand for data-driven insights in life sciences and healthcare. The company's strategic initiatives and strong cash reserve are expected to support its navigation through current challenges and towards achieving long-term success.
